Premium
P4‐132: A 3‐Year Analysis of the Progression of Amnestic Mild Cognitive Impairment
Author(s) -
Yoon Soo Jin,
Kim Eun-Joo,
Na Hae Ri,
Lee Jae-Hong,
Jeong Jee Hyang,
Seo Sang Won,
Na Duk L.,
Choi Seong Hye
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.2223
Subject(s) - dementia , cognitive impairment , visual memory , geriatric depression scale , audiology , depression (economics) , psychology , cognition , verbal memory , memory clinic , medicine , clinical psychology , psychiatry , disease , depressive symptoms , economics , macroeconomics
RPDwas 69 [47-92] years. 72% of patients were female. Symptoms began 1.2 [0.2-6.3] years prior to assessment, with an accelerated annualized rate of change in Clinical Dementia Rating Sum of Boxes (5.2 [0.6-36]). Modifying diagnoses were present in 17/47 (36%): most commonly, cerebrovascular disease (43%) and mood disorders (29%). Investigations routinely included neuroimaging (in all patients; 94% MRI), serum thyroid/B12 studies (77%), CSF analysis (51%), and electroencephalogram (32%). Additional CSF testing for ADand CJD-biomarkers was completed in 16 (34%) and 15 (32%) patients. AD-biomarkers were consistent with AD in 12 (75%) cases, including 2 patients with PPCD and onewith cerebral amyloid angiopathy with inflammation. CJD-biomarkers were not indicative of CJD in any patient. Conclusions: Common neurodegenerative dementing illnesses may present as RPD and can be reliably diagnosed using widely-available diagnostic tools. Measurement of AD and CJD biomarkers in the CSF may further inform the differential diagnosis for patients in whom the diagnosis remains uncertain.